Vasculogenic mimicry of acute leukemic bone marrow stromal cells

被引:0
作者
P Mirshahi
A Rafii
L Vincent
A Berthaut
R Varin
G Kalantar
C Marzac
O A Calandini
J-P Marie
C Soria
J Soria
M Mirshahi
机构
[1] UMRS 872,Department of Onco Haematology
[2] CNRS,Department of Onco Haematology
[3] E: 18,undefined
[4] INSERM,undefined
[5] Université Paris VI,undefined
[6] Groupe de recherches MERCI,undefined
[7] Faculté de Médecine et Pharmacie,undefined
来源
Leukemia | 2009年 / 23卷
关键词
angiogenesis; vasculogenic mimicry; insulin growth factor; bone marrow stromal cell; acute leukemia;
D O I
暂无
中图分类号
学科分类号
摘要
Angiogenesis is thought to be involved in the development of acute leukemia (AL). We investigated whether bone marrow stromal cells (BMSCs) derived from stem cells might be responsible for the increase in microvascular density (MVD), and compared 13 bone marrow samples from AL patients with 23 samples from patients in complete remission (controls). We demonstrated that AL-derived BMSC secreted more insulin growth factor-1 (IGF-1) and SDF-1α than controls. In addition, in contrast to normal adherent BMSCs, adherent BMSCs derived from CD133+/CD34+ stem cells from AL patients were able to form capillary-like structures (‘vasculogenic mimicry’) on Matrigel. The increase in vasculogenic mimicry occurred through PI3 kinase and ρ GTPase pathway as inhibitors of these signaling pathways (wortmannin and GGTI-298, respectively) were able to reduce or prevent capillary tube formation. In normal BMSC, addition of exogenous IGF-1 generated capillary-like tubes through the same pathway as observed spontaneously in AL-derived BMSC. The involvement of IGF-1 in the mimicry process was confirmed by the addition of a neutralizing antibody against IGF-1R or a IGF-1R pathway inhibitor (picropodophyllin). In conclusion, AL-derived BMSC present functional abnormalities that may explain the increase in MVD in the bone marrow of AL patients.
引用
收藏
页码:1039 / 1048
页数:9
相关论文
共 183 条
[1]  
Folkman J(1975)Tumor angiogenesis: a possible control point in tumor growth Ann Intern Med 82 96-100
[2]  
Moehler TM(2001)Angiogenesis in hematologic malignancies Ann Hematol 80 695-705
[3]  
Neben K(2000)Angiogenesis and angiogenic mediators in haematological malignancies Br J Haematol 111 43-51
[4]  
Ho AD(2007)Assessment of bone marrow angiogenesis in patients with acute myeloid leukemia by using contrast-enhanced MR imaging with clinically approved iron oxides: initial experience Radiology 242 217-224
[5]  
Goldschmidt H(2000)Evidence of increased angiogenesis in patients with acute myeloid leukemia Blood 95 309-2644
[6]  
Mangi MH(2000)Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia Blood 95 2637-821
[7]  
Newland AC(1997)Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia Am J Pathol 150 815-118
[8]  
Matuszewski L(2007)Angiogenesis and antiangiogenic therapy in hematologic malignancies Crit Rev Oncol Hematol 62 105-256
[9]  
Persigehl T(2002)Angiogenesis in hematologic malignancies and its clinical implications Int J Hematol 75 246-304
[10]  
Wall A(2001)Increased bone marrow vascularization in patients with acute myeloid leukemia: a possible role for vascular endothelial growth factor Br J Haematol 113 296-1930